trending Market Intelligence /marketintelligence/en/news-insights/trending/k4PZUfXS9MhFV0Q9VWkIQQ2 content esgSubNav
Log in to other products

 /


Looking for more?

Contact Us
In This List

Japan's Hisamitsu seeks US FDA nod for schizophrenia therapy

Blog

COVID-19 Impact & Recovery: Healthcare Outlook for H2 2021

Video

Climate Credit Analytics: Linking climate scenarios to financial impacts

Blog

Global M&A Infographic Q1 2021

Blog

Q1 2021 Global Capital Markets Activity: SPAC IPOs, Issuance in Consumer Discretionary Sector Surge


Japan's Hisamitsu seeks US FDA nod for schizophrenia therapy

Japan's Hisamitsu Pharmaceutical Co. Inc. and its U.S. unit Noven Pharmaceuticals Inc. submitted an application seeking U.S. Food and Drug Administration approval for schizophrenia treatment HP-3070.

Schizophrenia is a chronic and severe mental disorder that affects how a person thinks, feels and behaves.

HP-3070, or asenapine maleate, is a patch placed on the skin to deliver medication into the bloodstream. The transdermal therapy was previously shown to improve symptoms of the disorder in a late-stage study.